AD17002 Intranasal Spray

AD17002 · Advagene Biopharma Co. Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for AD17002 Intranasal Spray, covering 2025-09-10 to 2025-09-10. Get the full timeline:

Most recent: Clinical Trial Update: Evaluating the Safety and Efficacy of AD17002 Intranasal Spray in Treating Participants With Mild to Moderate COVID-19 [Phase 2, Phase 3]

See pricing